Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions by Denise A. Yardley
Breast Cancer: Basic and Clinical Research 2013:7 7–22
doi: 10.4137/BCBCR.S10071
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Breast Cancer: Basic and Clinical Research
Review
Breast Cancer: Basic and Clinical Research 2013:7  7
combining mTOR Inhibitors with chemotherapy and Other 
Targeted Therapies in Advanced Breast cancer: Rationale, 
clinical experience, and Future Directions
Denise A. Yardley
Sarah Cannon Research institute, Nashville, Tennessee, USA. Corresponding author email: dyardley@tnonc.com
Abstract: Improvements in survival of patients with breast cancer have been attributed to the development of agents that target key com-
ponents of dysregulated pathways involved in oncogenesis and progression of breast cancer. Aberrant mammalian target of rapamycin 
(mTOR) activation has been implicated in oncogenesis, angiogenesis, and the development of estrogen independence and resistance to 
chemotherapy in breast tumors. Several mTOR inhibitors (sirolimus, everolimus, temsirolimus, and ridaforolimus) have demonstrated 
antitumor activity in breast cancer cells. Combining mTOR inhibitors with endocrine therapies has demonstrated clinical antitumor 
activity in patients with metastatic breast cancer. In addition, mTOR inhibitor combinations with various targeted biologic agents or 
cytotoxic chemotherapeutic agents are being examined in more than 40 clinical trials with some early promising results. Combination 
therapies targeting multiple components of these central signaling pathways may be an optimal treatment strategy for patients with 
advanced breast cancer.
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Introduction
Improvements in overall or disease-free survival of 
patients with breast cancer have been attributed in 
part to the identification of dysregulated cell signal-
ing pathways and the recent development of therapies 
that target key components of these pathways.1 Some 
of these targets include vascular endothelial growth 
factor (VEGF) and its receptors (VEGFRs), epider-
mal growth factor receptor (EGFR) and human epi-
dermal growth factor receptor 2 (HER2), and insulin 
growth factor receptors (IGFRs).2 Monotherapy drug 
strategies aimed at these targets have yielded modest 
results in breast cancer trials, and many patients sub-
sequently develop resistance to these agents. Despite 
these  limitations,  the  role  of  cell  signaling  among 
these various pathways is clearly evident. Therapeutic 
agents in combination that target the aforementioned 
growth factors and/or their receptors represent an area 
of active investigation that has produced promising 
results, with some notable exceptions.2
Mammalian  target  of  rapamycin  (mTOR)  is  a 
  serine/threonine kinase that integrates multiple sig-
nals from growth factors and hormones3,4 and plays a 
central role in the control of cell growth, proliferation, 
and angiogenesis.4,5 Aberrant mTOR activation has 
been  implicated  in  oncogenesis,  angiogenesis,  and 
the development of drug resistance in tumor cells.6–9 
A high proportion of breast tumors exhibit constitu-
tive activation of the mTOR pathway.10 Convergence 
of multiple signaling pathways toward a central medi-
ator, such as mTOR, lends itself to the hypothesis that 
targeting multiple pathways, including mTOR, with 
different classes of agents may be a more effective 
treatment  strategy  than  monotherapy  approaches.11 
Several mTOR inhibitors have been developed and 
evaluated  in  combination  with  chemotherapy,  hor-
monal therapies, and other targeted biologic agents 
to investigate the utility of combination therapy for 
patients with advanced breast cancer.
Overview of the mTOR pathway
Endocrine and growth factor receptors involved in 
the pathogenesis of breast cancer have been shown 
to activate mTOR through phosphoinositide 3-kinase 
(PI3K)/Akt signaling (Fig. 1).12,13 Multiple upstream 
signaling  components  of  this  pathway,  such  as 
the  estrogen  receptor  (ER),14  the  receptor  tyrosine 
kinase HER2,15 VEGFR, IGF-1R, phosphatase and 
tensin homolog (PTEN), Akt (also known as protein 
kinase  B),16  PI3K,  and  the  PI3K  catalytic  subunit 
(PI3KCA),17  become  deregulated  in  breast  cancer 
and  are  thought  to  play  a  role  in  its  development 
and  progression.18,19  Therefore,  inhibiting  mTOR 
potentially  interferes  with  breast  cancer  progres-
sion at multiple levels. Preclinical evidence demon-
strates that the PI3K/Akt/mTOR pathway is involved 
in the response of breast cancer cells to hormonal 
therapies,13 chemotherapy,20 and targeted agents.21,22 
Members  of  the  EGFR  family,  including  HER2, 
use  the  PI3K/Akt/mTOR  pathway  to  promote  cell 
growth  and  survival.22  Overexpressed  in  approxi-
mately 20% of invasive breast cancers and associated 
with  a  poor  prognosis,23,24  HER2-mediated  activa-
tion of the PI3K/Akt/mTOR pathway is predictive 
of tumor progression in breast cancer22 and has been 
implicated in angiogenesis and metastasis of breast 
cancer cells.15 Trastuzumab, a monoclonal antibody 
that binds to the extracellular domain of HER2, has 
been shown to diminish HER2-mediated signaling, 
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Figure 1. The Pi3K/Akt/mTOR pathway.13 
From Lane H, Lebwohl D. Future directions in the treatment of hormone-
sensitive advanced breast cancer: the RAD001 (everolimus) letrozole 
clinical program. 
Reprinted with permission from elsevier.13
Abbreviations: 4e-BPs, 4 eukaryotic binding proteins; eiF4K,   eukaryotic 
initiation factor 4K; mTORC, mammalian target of rapamycin complex; 
PTeN, phosphatase and tensin homolog; S6K1, ribosomal protein S6 
kinase 1; S6, ribosomal protein S6; TSC1, tuberous sclerosis complex1; 
TSC2, tuberous sclerosis complex 2; Pi3K, phosphoinositide 3-kinase; 
eGFR,  epidermal  growth  factor  receptor;  HeR2,  human  epidermal 
growth   factor receptor 2; iGF-1R, insulin growth factor 1; Akt/PKB, pro-
tein kinase B; AMPK, AMP-activated protein kinase; LKB1, liver kinase 
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including   activation of the PI3K/Akt/mTOR pathway 
in vitro.25 In HER2-positive breast cancer cell lines, 
trastuzumab inhibited the feedback loop activation 
of Akt.26 In addition, lapatinib, a specific dual inhibi-
tor of HER2 and EGFR tyrosine kinase activity, has 
been shown to induce cell cycle arrest and apopto-
sis by inhibiting HER2-activated signaling pathways 
including PI3K/Akt/mTOR.27
In  cells  demonstrating  trastuzumab  resistance, 
amplified  signaling  through  both  the  PI3K/Akt/
mTOR and MAPK pathways is evident in the pres-
ence of elevated levels of activated receptor tyrosine 
kinase Eph receptor A2 (EphA2).28 Involvement of 
the mTOR pathway in HER2-positive trastuzumab-
resistant patients is further supported by preliminary 
biomarker  analyses  from  the  neoadjuvant  phase  3 
GeparQuattro  study  (NCT00288002),29  evaluating 
the addition of capecitabine and/or trastuzumab (in 
HER2-positive  patients  only)  to  epirubicin/cyclo-
phosphamide  followed  by  docetaxel  combination 
chemotherapy.  Increased  levels  of  phosphorylated 
eIF4E-binding  protein  (4E-BP1),  a  substrate  of 
mTOR,  have  been  detected  in  the  HER2-positive 
cohort of patients resistant to trastuzumab-cytotoxic 
therapy.30 This contribution of mTOR to resistance 
will  be   further  validated  in  the  ongoing  phase  3 
GeparQuinto  study  (NCT00567554)29  investigating 
the integration of bevacizumab, everolimus, and lap-
atinib into neoadjuvant chemotherapy regimens.
Since the discovery of the key role of mTOR in 
the regulation of cell growth and proliferation, cell 
metabolism, angiogenesis, and apoptosis, two mTOR 
complexes have been identified: mTORC1, composed 
of  mTOR,  regulatory-associated  protein  of  mTOR 
(RAPTOR),  and  mTOR-associated  protein,  LST8 
homolog  (mLST8  [GβL]),  which  regulates  protein 
synthesis, cell growth and proliferation, cell metabo-
lism, and angiogenesis; and mTORC2, composed of 
mTOR, rapamycin-insensitive companion of mTOR 
(RICTOR),  mLST8,  and  sin1,  which  phosphory-
lates the kinase Akt and drives full activation of Akt 
when combined with pyruvate dehydrogenase kinase 
isoenzyme 1 (PDK1).31 New agents are being devel-
oped that can inhibit both mTORC1 and mTORC2 
and affect the activation of Akt, to limit constitutive 
downstream mTOR activation (Table 1).32–39
A key component of the mTOR pathway is the lipid 
kinase  PI3K,  which  affects  survival,    proliferation, 
growth,  shape,  migration,  and  intracellular    sorting 
in  tumor  development.40  Three  classes  of  PI3K 
enzymes, designated I to III, have been identified; 
members of PI3K class I have been implicated in the 
mTOR pathway and are a focus of potential therapy 
for solid tumors.40 Agents such as BEZ235, PI-103, 
and XL765 are dual PI3K/mTOR inhibitors, which 
may  bypass  feedback  loops,  potentially  increasing 
their  efficacies.41  These  agents  are  currently  being 
evaluated in clinical trials and may provide targeted 
therapeutic  combinations  that  are  effective  against 
solid tumors.18,41
Approved and Investigational  
mTOR Inhibitors
Several  mTOR  inhibitors  have  been  developed 
and  evaluated  as  antitumor  therapies,  with  some 
distinctive  differences  in  metabolism,  formula-
tion, and schedule of administration (Table 1).32,38,42 
Three agents have received United States Food and 
Drug  Administration  (FDA)  approval  (sirolimus, 
everolimus,  and  temsirolimus),  and  two  of  these 
  (sirolimus and everolimus) are oral agents. Sirolimus 
  (rapamycin), an agent that partially inhibits mTOR,43 
is approved for the prevention of kidney transplant 
rejection and has been investigated in combination 
with various agents to determine its clinical activity 
in breast cancer (Fig. 2A).29,44,45 Analogs of sirolimus 
demonstrating  more  favorable  pharmacokinetics 
include  temsirolimus,  everolimus,  and  ridaforoli-
mus    (formerly  deforolimus)  (Fig.  2B–D).42,46,47 
  Temsirolimus,  approved  for  the  treatment  of 
advanced renal cell carcinoma (RCC),46 is a prodrug, 
and its primary active metabolite is rapamycin (half-
life approximately 17 to 55 hours).46 In breast cancer 
  trials, as for RCC, temsirolimus is administered by 
a weekly intravenous infusion. Everolimus (half-life 
approximately 30 hours), another analog of siroli-
mus, is approved for the treatment of advanced RCC 
and progressive neuroendocrine tumors of pancre-
atic origin (PNET) at a dosage of 10 mg/day, adults 
with renal angiomyolipoma and tuberous sclerosis 
complex (TSC) not requiring immediate surgery at 
a dosage of 10 mg/day, and subependymal giant cell 
astrocytomas  (SEGAs)  associated  with  tuberous 
sclerosis  at  a  dosage  of  5  mg/day.47  Everolimus 
recently (July 2012) received FDA approval for the 
treatment of postmenopausal women with advanced Yardley
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epoxy-3H-pyrido[2,1-c][1,4] oxaazacyclohentriacontine-1,5,11,28,29 
(4H, 6H,31H)-pentone.
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Figure 2B. everolimus.47
notes:(1R,9S,12S,15R,16e,18R,19R,21R,23S,24e,26e,28e, 
30S,32S,35R)-1,18-dihydroxy-12-{(1R)-2-[(1S,3R,4R)-4-(2-
hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-
15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]
hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone.
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Figure 2c. Temsirolimus.46
notes: (3S,6R,7e,9R,10R,12R,14S,15e,17e,19e,21S,23S,26R,27R,34
aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-
9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-
1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23, 
27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1, 
5,11,28,29(4H,6H,31H)-pentone  4′-[2,2-bis(hydroxymethyl)propionate]; 
or Rapamycin, 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate.
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Figure 2D. Ridaforolimus.42
notes:(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16e,18R,19R,21R, 
23S,24e,26e,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-
15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-
4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]
propyl]-2-methoxycyclohexyl dimethylphosphinate.
hormone  receptor-positive,  HER2-negative  breast 
cancer in combination with exemestane after failure 
of treatment with letrozole or anastrozole at a dosage 
of 10 mg/day.47 Ridaforolimus remains an investiga-
tional analog of sirolimus (half-life 49 hours) that is 
administered orally in breast cancer trials at 40 mg/day 
for  5  days/week  (NCT01234857,  NCT01220570, 
and  NCT00736970).29,48  Overall,  these  different 
mTOR inhibitors share class-specific toxicities such 
as stomatitis, noninfectious pneumonitis, infection, 
hyperglycemia, and dyslipidemia.45–48
mTOR Inhibition in combination  
with chemotherapy
A variety of chemotherapeutic regimens are used in 
the treatment of patients with metastatic breast can-
cer (mBC); however, most tumors eventually develop Yardley
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resistance,  necessitating  a  change  in  treatment. 
Because the mTOR pathway is upregulated in many 
chemoresistant cancers, mTOR inhibitors are a logi-
cal choice to resensitize tumor cells to chemotherapy 
or delay the development of treatment resistance by 
these upregulated or mutated key pathways.
Preclinical evidence
Preclinical  studies  suggest  that  one  mechanism  of 
chemoresistance to paclitaxel and carboplatin is overex-
pression of HER2.49 In breast cancer models with HER2 
overexpression, the combination of an mTOR inhibitor 
with  paclitaxel,  carboplatin,  or  vinorelbine  enhances 
apoptosis of the cells in vitro and antitumor efficacy in 
mouse xenograft models in vivo compared with either 
agent  alone.49  Moreover,  the  combination  of  mTOR 
inhibitors  with  cytotoxic  agents  demonstrates  syner-
gistic antiproliferative cellular activity irrespective of 
HER2 signaling, further suggesting the potential clinical 
utility of combination therapy for patients with breast 
cancer  that  has  become  resistant  to  chemotherapy.49
Clinical studies in HeR2-positive  
and HeR2-negative mBC
A number of nonrandomized studies in HER2-positive 
trastuzumab-resistant  mBC  have  shown    antitumor 
activity with the addition of everolimus to standard 
chemotherapy  plus  trastuzumab  (Table  2).  Several 
phase  1  studies  have  been  undertaken  to  evaluate 
the  tolerability  and  activity  of  these  combinations. 
In a phase 1 study of 47 evaluable heavily pretreated 
HER2-  positive  mBC  patients  progressing  while 
receiving trastuzumab and subsequently treated with 
everolimus plus vinorelbine and trastuzumab, the over-
all response rate (ORR) was 19%, with a disease con-
trol rate of 83% and median progression-free survival 
(PFS) of 30.7 weeks.50 The optimal dosing of everoli-
mus in combination with vinorelbine and trastuzumab 
was determined to be 5 mg/day.50 In a second, smaller 
phase 1 study conducted in this same resistant HER2-
positive mBC patient population, subsequent treatment 
with everolimus in combination with paclitaxel plus 
trastuzumab yielded an ORR of 44%; overall disease 
Table 2. Registered combination clinical trials of everolimus in patients with HeR2-positive breast cancer.29
ncT ID/title Receptor status Drug  
treatments
phase n*
NCT00458237/Dose escalation Followed by Study of  
everolimus in Combination with Trastuzumab in HeR2- 
Positive Metastatic Breast Cancer
HeR2-positive everolimus 
Trastuzumab
1/2 11
NCT00317720/Trastuzumab and everolimus in Patients  
with HeR2 Overexpressing Breast Cancer
HeR2-positive everolimus 
Trastuzumab
1/2 47
NCT00674414/Trastuzumab with or without everolimus in  
Treating women with Breast Cancer That Can Be Removed  
by Surgery
HeR2-positive everolimus 
Trastuzumab
2 120
NCT00426556/Efficacy and Safety of Everolimus in  
Combination Therapy, in Patients with HeR2- 
Overexpressing Metastatic Breast Cancer
HeR2-positive everolimus 
Paclitaxel  
Trastuzumab
1/2 90
NCT01163929/A Study to Look at the Combination of  
Chemotherapy, Trastuzumab and everolimus in HeR2- 
Positive Breast Cancer
HeR2-positive everolimus  
Paclitaxel 
Trastuzumab
2 30
NCT00876395/BOLeRO-1 everolimus in Combination  
with Trastuzumab and Paclitaxel in the Treatment of HeR2- 
Positive Locally Advanced or Metastatic Breast Cancer
HeR2-positive everolimus  
Trastuzumab 
Paclitaxel
3 717
NCT01007942/BOLeRO-3 Daily everolimus in Combination  
with Trastuzumab and vinorelbine in HeR2/Neu Positive  
women with Locally Advanced or Metastatic Breast Cancer
HeR2-positive everolimus 
vinorelbine
Trastuzumab
3  572 
NCT01283789/Lapatinib and RAD001 for HeR2 Positive  
Metastatic Breast Cancer
HeR2-positive Lapatinib 
RAD001
2 45
note: *Actual or anticipated enrollment.
Abbreviation: HeR2, human epidermal growth factor receptor 2.Combining mTOR inhibitor with chemotherapy or targeted therapy
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was controlled for $6 months in 74% of patients, and 
the median PFS was 34 weeks.51 The optimal dosing of 
everolimus in combination with paclitaxel and trastu-
zumab was determined to be 10 mg/day.51
In HER2-negative mBC, everolimus phase 1 com-
binations have included evaluations with a weekly 
cisplatin/paclitaxel doublet. In 13   evaluable patients 
with advanced HER2-negative mBC with a median 
of 3 previous chemotherapy regimens treated with 
everolimus and weekly cisplatin/  paclitaxel, 1 com-
plete response, 2 partial responses, 7 stable diseases, 
and 3 disease progressions were noted.52 In a similar 
study of HER2-negative, hormone receptor-positive 
mBC treated with the combination of capecitabine 
plus everolimus, a nearly identical pattern of response 
was seen, with 2 partial responses and 7 stable dis-
eases in 12 evaluable patients.53 Additional studies 
assessing a variety of everolimus/chemotherapy com-
binations are ongoing (Table 3).29
On  the  basis  of  these  promising  results  and 
those  generated  from  other  studies,  24  registered 
clinical  trials—7  of  which  include  HER2-positive 
patients—are  evaluating  the  efficacy  of  everoli-
mus in combination with varying chemotherapeutic 
agents (Tables 2–5)29 in a variety of disease settings. 
Two  international,  double-blind,  placebo-  controlled 
phase  3  studies  have  been  initiated  to  assess  the 
addition  of  everolimus  to  trastuzumab-containing 
chemotherapy  regimens  in  women  with  HER2-
  positive locally advanced or mBC (Table 2).29 In the 
  BOLERO-1  (Breast  cancer  trials  of  oraL  everoli-
mus)  study,  717  patients  with  untreated  metastatic 
HER2-  positive  breast  cancer  have  been  randomly 
assigned to receive first-line weekly paclitaxel plus 
Table 3. Registered combination clinical trials of everolimus in patients with HeR2- and/or triple-negative breast cancer.29
ncT ID/title Receptor status Drug treatments phase n*
NCT01272141/A Study of Lapatinib in  
Combination with everolimus in Patients  
with Advanced, Triple Negative Breast Cancer
Triple-negative everolimus  
Lapatinib
2 43
NCT00499603/Paclitaxel Followed by  
5-Fluorouracil, epirubicin, Cyclophosphamide  
(FeC) versus Paclitaxel and everolimus  
Followed by FeC in women with Breast Cancer
Triple-negative everolimus  
Paclitaxel  
5-Fluorouracil  
epirubicin  
Cyclophosphamide
2 50
NCT01031446/Cisplatin, Paclitaxel, and  
everolimus in Treating Patients with  
Metastatic Breast Cancer
Triple-negative 
HeR2-negative
everolimus  
Cisplatin  
Paclitaxel
1/2 55
NCT00915603/Placebo-Controlled Trial of  
weekly Paclitaxel/Bevacizumab +/- everolimus  
as First-Line Chemotherapy
HeR2-negative everolimus 
Paclitaxel 
Bevacizumab
2 110
NCT00567554/exploring the integration of  
Bevacizumab, everolimus, and Lapatinib into  
Current Neoadjuvant Chemotherapy Regimens  
for Primary Breast Cancer (GeparQuinto)
HeR2-negative or 
HeR2-positive
everolimus  
epirubicin  
Cyclophosphamide  
Docetaxel  
Bevacizumab  
Paclitaxel  
Trastuzumab  
Lapatinib
3 2547
NCT00930930/A Phase ii Neo-Adjuvant  
Study of Cisplatin, Paclitaxel with or without  
RAD001 in Patients with Triple-negative Locally  
Advanced Breast Cancer
Triple-negative everolimus
Cisplatin  
Paclitaxel  
Placebo
2 102
NCT00934895/Phase i/ii Study of weekly  
Abraxane and RAD001 in women with Locally  
Advanced or Metastatic Breast Cancer
HeR2-negative everolimus  
Albumin-bound Paclitaxel
1/2 72
note: *Actual or anticipated enrollment.
Abbreviation: HeR2, human epidermal growth factor receptor 2.Yardley
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Table 4. Registered combination clinical trials of everolimus in patients with HeR2-negative hormone receptor-positive 
breast cancer.29
ncT ID/title Hormone status Drug  
treatments
phase n*
NCT00912340/Randomized Phase ii Trial of Trastuzumab or  
everolimus in Hormone-refractory Metastatic Breast Cancer
eR-positive and/or  
PR-positive;  
HeR2-negative
everolimus  
Trastuzumab
2 80
NCT00107016/everolimus and Letrozole as Preoperative  
Therapy of Primary Breast Cancer in Post-menopausal women
eR-positive everolimus  
Letrozole
2 255
NCT01298713/Tamoxifen-RAD001 versus Tamoxifen Alone in  
Patients with Anti-aromatase Resistant Breast Metastatic Cancer
eR-positive and/or  
PR-positive;  
HeR2-negative
everolimus  
Tamoxifen
2 111
NCT00570921/Study of Combined Fulvestrant and everolimus in  
Advanced/Metastatic Breast Cancer After Aromatase inhibitor Failure
eR-positive and/or  
PR-positive
everolimus  
Fulvestrant
2 44
NCT00863655/BOLeRO-2 everolimus in Combination with  
exemestane in the Treatment of Postmenopausal women with  
estrogen Receptor Positive Locally Advanced or Metastatic  
Breast Cancer who Are Refractory to Letrozole or Anastrozole
eR-positive 
HeR2-negative
everolimus 
exemestane
3 705
NCT01231659/Safety and Efficacy of Everolimus in Combination  
with Letrozole in the Treatment of Postmenopausal women with  
Locally Advanced or Metastatic Breast Cancer
eR-positive everolimus 
Letrozole
4 70
note: *Actual or anticipated enrollment.
Abbreviation: eR, estrogen receptor; HeR2, human epidermal growth factor receptor 2; PR, progesterone receptor.
Table 5. Registered combination clinical trials of everolimus in patients with receptor status not specified.29
ncT ID/title Receptor 
status
Drug  
treatments
phase n*
NCT00930475/everolimus and Carboplatin  
in Pretreated Metastatic Breast Cancer
NS everolimus  
Carboplatin
1/2 54
NCT00253318/everolimus Plus Docetaxel  
in Patients with Metastatic Breast Cancer
NS everolimus  
Docetaxel
1/2 15
note: *Actual or anticipated enrollment.
Abbreviation: NS, not specified. 
trastuzumab with or without 10 mg/day of everolimus. 
The   BOLERO-3 study is evaluating 572 patients with 
HER2-positive mBC previously treated with a tax-
ane and resistant to trastuzumab. These patients have 
been randomly assigned to receive vinorelbine plus 
trastuzumab with or without 5 mg/day of everolimus. 
A  third  BOLERO  trial,  BOLERO-2,  recruited  724 
postmenopausal women with HER2-negative, locally 
advanced breast cancer or mBC refractory to letro-
zole or anastrozole who have been randomly assigned 
to receive exemestane with or without everolimus. In 
earlier-stage  disease,  the  neoadjuvant  GeparQuinto 
phase 3 European trial evaluated the addition of beva-
cizumab,  everolimus,  or  lapatinib  in  2547  patients 
with  varied  hormone  status  treated  with  current 
neoadjuvant chemotherapy regimens (Table 3).29 Pre-
liminary  results  did  not  show  a  significant  clinical 
advantage for the addition of bevacizumab to standard 
chemotherapy and demonstrated reduced efficacy with 
lapatinib versus trastuzumab in   combination with epi-
rubicin/cyclophosphamide before surgery.54 Addition-
ally, recent results from the study arm evaluating the 
addition of everolimus to paclitaxel in HER2-negative 
patients  after  epirubicin/cyclophosphamide/bevaci-
zumab suggest that adding everolimus to paclitaxel 
did not significantly improve pathological complete 
response rates compared with paclitaxel alone.55
Other  mTOR  inhibitors  also  are  under  evalu-
ation  in  both  HER2-negative  and  HER2-positive 
mBC disease settings. One such trial is evaluating Combining mTOR inhibitor with chemotherapy or targeted therapy
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Table 6. Registered combination clinical trials of other mTOR inhibitors in patients with breast cancer.29
ncT ID/title Hormone status Drug treatments phase n*
NCT00411788/A Phase 2 Study of  
Rapamycin and Trastuzumab for Patients  
with HeR2 Receptor Positive mBC
HeR2-positive Sirolimus  
Trastuzumab
2 30
NCT00736970/Oral Deforolimus with  
Trastuzumab for Patients with HeR2+  
Trastuzumab-Refractory mBC (8669-009)
HeR2-positive Ridaforolimus 
Trastuzumab
2 34
NCT01234857 A Study of Ridaforolimus  
(MK-8669) in Combination with  
Dalotuzumab (MK-0646) Compared to  
Standard of Care Treatment in eR+ Breast  
Cancer Patients (MK-8669-041)
eR-positive; 
HeR2-negative
Ridaforolimus 
Dalotuzumab 
exemestane
2 352
NCT01082068/Study of XL147 or XL765 in  
Combination with Letrozole in Subjects  
with Breast Cancer
eR-positive and/or  
PR-positive 
HeR2-negative
XL765 
XL147 
Letrozole
1/2 124
note: *Actual or anticipated enrollment.
Abbreviations: eR, estrogen receptor; HeR2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer; PR, progesterone receptor.
Table 7. Registered combination clinical trials of temsirolimus in patients with breast cancer.29
ncT ID/title Receptor status Drug treatments phase n*
NCT00061971/Letrozole with or without CCi- 
779 in Treating Postmenopausal women with  
Locally Advanced or Metastatic Breast Cancer
eR-positive and/or  
PR-positive
Temsirolimus  
Letrozole
2 108
NCT00062751/Study evaluating Temsirolimus  
in Breast Neoplasms
eR-positive and/or  
PR-positive
Temsirolimus  
Letrozole
2 108
NCT00699491/Cixutumumab and  
Temsirolimus in Treating Patients with Locally  
Recurrent or Metastatic Breast Cancer
NS Temsirolimus 
Cixutumumab 
(iMC-A12)
1/2   68
NCT01111825/A Phase 1/2 Trial of  
Temsirolimus Plus Neratinib for Patients  
with Metastatic HER2-Amplified or  
TN Breast Cancer
HeR2-positive or  
triple-negative
Temsirolimus 
Neratinib 
(HKi-272)
1/2   65
note: *Actual or anticipated enrollment.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NS, not specified; PR, progesterone receptor; TN, triple-
negative.
sirolimus with trastuzumab in HER2-positive mBC 
(Table  6).29  Temsirolimus,  an  mTOR  inhibitor 
approved for the treatment of advanced RCC, is being 
evaluated in several mBC trials in combination with 
chemotherapy as well as with other biologic targeted 
agents. In patients with locally recurrent or mBC, the 
  combination of cixutumumab, a monoclonal antibody 
that  is  an  IGF-1R  antagonist,  and  temsirolimus  is 
undergoing evaluation in a phase 1/2 trial to character-
ize the tolerability and toxicity profile, recommended 
dose level, and antitumor activity (in terms of ORR) 
(NCT00699491).29 As in BOLERO 3, temsirolimus is 
also being evaluated in combination with vinorelbine 
ditartrate in patients with unresectable or metastatic 
solid tumors (NCT01155258).29 Both locally recur-
rent or unresctable locally advanced breast cancers 
in addition to mBC are eligible along with several 
other tumor types to determine the maximal tolerated 
dose  for  this  temsirolimus  and  vinorelbine  combi-
nation as well as to obtain preliminary information 
regarding the activity, safety, and tolerability of this 
  combination.29 Neratinib, a dual inhibitor of HER2 
and EGFR kinases, is also being combined with temsi-
rolimus in an open-label, single-arm, dose-escalation 
phase  1/2  study  to  determine  the  maximum  toler-
ated dose, safety, and efficacy of this combination in Yardley
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advanced breast cancer (Table 7) (NCT01111825).29 
The phase 1 portion of the study will examine this 
combination in patients with trastuzumab-refractory 
HER2-amplified  disease  or  triple-negative  disease, 
whereas the phase 2 portion will study each recep-
tor type separately.29 Results from these and other 
studies will help to determine the benefit of temsi-
rolimus  combination  therapy  in  advanced  breast 
cancer. Unfortunately, the results of a larger, random-
ized, phase 3 trial in approximately 900 women with 
hormone receptor-positive mBC, evaluating first-line 
treatment with temsirolimus (10 mg/day or 30 mg/
day for 5 days every 2 weeks) in combination with 
the aromatase inhibitor letrozole (2.5 mg/day) versus 
letrozole (2.5 mg/day) alone, failed to demonstrate 
clinical benefit.56 This large trial was closed prema-
turely, and it has been postulated that the surprising 
lack of activity has been attributed to both the dose 
and schedule of temsirolimus as well as the possibil-
ity that the first-line mBC disease setting may not be 
the best setting to assess the impact of mTOR inhibi-
tion, which may be more prevalent with later lines 
of disease as the mTOR signaling pathway may not 
have been fully activated.29
mTOR Inhibition in combination  
with HeR2-Targeted Therapy
As discussed, trastuzumab with or without an Akt/
mTOR  pathway  inhibitor25,26  and  lapatinib27  have 
been shown to exert antitumor effects by inhibiting 
HER2-activated signaling pathways, including PI3K/
Akt/mTOR. A combination of HER2-targeted agents 
and  mTOR  inhibitors  has  demonstrated  antitumor 
activity  in  resistant  breast  cancer  cells,  suggesting 
that mTOR inhibitors may have the potential to delay 
or  prevent  acquired  resistance  to  HER2-targeted 
agents.57 Furthermore, PI3K pathway activation due 
to low expression/loss of function of PTEN and/or 
mutations in the PI3KCA gene has been identified as 
a major determinant of poor treatment success of tras-
tuzumab- and lapatinib-based therapy in patients with 
HER2-overexpressing breast cancer.20,58 Thus, using 
mTOR inhibitors to restore or enhance trastuzumab 
sensitivity is a rational approach.
Preclinical evidence
Preclinical  studies  in  HER2-overexpressing  mouse 
tumors and cell lines suggest that PI3K/Akt/mTOR 
pathway inhibition is required for optimal antitumor 
effects of HER2 antagonists57 and may be a clinically 
applicable strategy for overcoming trastuzumab resis-
tance caused by hyperactivation of the PI3K pathway 
due to PTEN deficiency.20,26 In vitro, low doses of 
everolimus significantly increased growth inhibition 
by trastuzumab; everolimus also enhanced the antitu-
mor efficacy of trastuzumab in vivo in mouse xeno-
graft models.26
Clinical studies
Results of phase 1 studies in patients with HER2-
overexpressing mBC resistant to trastuzumab showed 
that everolimus is well tolerated in combination with 
trastuzumab and paclitaxel or vinorelbine and that the 
combination had antitumor activity and formed the 
basis  of  the  now  closed,50,51  previously    mentioned 
phase  3  trials  of  everolimus  with  chemotherapy 
and  trastuzumab  in  patients  with  HER2-positive 
mBC  (BOLERO-1  [NCT00876395],  BOLERO-3 
[NCT01007942]).29  As  noted  above,  several  clini-
cal studies are exploring the potential of everolimus 
as well as other mTOR inhibitors for improving the 
efficacy  of,  or  overcoming  resistance  to,  HER2-
targeted  therapy  as  outlined  above  with  sirolimus 
and   temsirolimus. These combinations of an mTOR 
inhibitor with select antimicrotubule agents demon-
strate antitumor activity in patients refractory to both 
trastuzumab and taxanes.50
mTOR Inhibition in combination  
with endocrine Therapy
The ER is expressed in approximately 30% of pre-
menopausal patients with breast cancer and 60% to 
70% of postmenopausal patients with breast cancer 
and has a significant role in cancer cell proliferation 
and metastasis.59–62 Approximately 30% of patients 
with ER-positive breast cancer are intrinsically resis-
tant  to  hormonal  therapies,  and  the  remainder  of 
patients  eventually  acquire  resistance  to  hormonal 
therapy.63 In 25% of primary breast cancers, muta-
tions in PI3 KCA have been identified and are associ-
ated with the development of resistance to therapy.20 
Endocrine resistance has been associated with dys-
regulated  PI3K/Akt/mTOR  signaling,  and  it  is 
hypothesized that cross-talk between the ER path-
way and the PI3K/Akt/mTOR pathway underlies this 
mechanism of resistance to endocrine therapy.10,64,65 Combining mTOR inhibitor with chemotherapy or targeted therapy
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For example, ER has been shown to activate tyrosine 
kinase receptors, resulting in the activation of down-
stream resistance pathways such as ERK/MAPK and 
PI3K/Akt.64 It is hypothesized that the addition of an 
mTOR inhibitor may restore antitumor response to 
endocrine therapy.65,66
Preclinical evidence
In preclinical breast cancer models using MCF-7 cells 
with  constitutively  active  Akt/mTOR  that  exhibit 
hormone and chemotherapy resistance, mTOR inhib-
itors enhanced the efficacy of selective ER modu-
lators  tamoxifen,  raloxifene,  and  ERA-92367;  the 
ER downregulator fulvestrant66; and the aromatase 
inhibitor letrozole.68 In addition, dual inhibition of 
mTOR and ER signaling in cellular models of breast 
cancer was shown to have a synergistic effect on cell 
cycle arrest and induction of   apoptosis.69 The strat-
egy of combination therapy of a selective ER modu-
lator with rapamycin or temsirolimus has also been 
shown to restore sensitivity to endocrine therapy in 
breast cancer cells and may be attributed to the return 
of normal apoptotic response to endocrine therapy.70 
In fact, the   BOLERO-2 trial was based on the pre-
clinical    combination  therapy  data  with  letrozole 
plus everolimus shown to restore sensitivity to letro-
zole in breast cancer cells by inhibiting cell cycle 
progression  and  triggering  apoptotic  cell  death.68 
Additionally,  a  phase  1  dose-escalating  study  that 
evaluated  everolimus  plus  letrozole  in  postmeno-
pausal women or men with stable mBC or progres-
sion after $ 4 months of first- or second-line therapy 
with letrozole alone found that an everolimus dose of 
10 mg/day provided antitumor activity with no phar-
macokinetic interactions.71
Clinical studies
Several clinical studies have explored and reported 
results  for  the  potential  of  mTOR  inhibitors  to 
improve efficacy or overcome resistance to endocrine 
therapy.  Recently  reported  robust  results  from  the 
international randomized, placebo-controlled, phase 
3  study  (BOLERO-2,  NCT00863655)  have  gener-
ated  the  most  enthusiasm  and  excitement  for  the 
further advancement of mTOR inhibitors in breast 
cancer. The first of the BOLERO trials evaluating 
everolimus in mBC, BOLERO-2, evaluated the com-
bination of everolimus and exemestane in patients 
with  ER-positive  mBC  refractory  to  letrozole  or 
anastrozole,  demonstrating  that  the  addition  of 
everolimus  to  exemestane  significantly  improved 
PFS (Table 4).29 In an interim analysis, median PFS 
was 6.9 months for everolimus plus exemestane com-
pared with 2.8 months for exemestane plus placebo, 
corresponding to a 57% reduction in the hazard ratio 
(HR = 0.43, 95% confidence interval [CI], 0.35–0.54, 
P , 0.001 [local assessment]).72 A longer-term pre-
specified 12-month follow-up analysis of BOLERO-2 
was conducted, with results confirming the benefit 
reported with shorter follow-up with a median PFS 
now at 7.4 months versus 3.2 months for exemes-
tane only (HR = 0.44, 95% CI, 0.36–0.53, P , 0.001 
[local assessment]).73 Furthermore, the median dose 
intensity (cumulative dose/duration of exposure) of 
everolimus was 8.6 mg (range, 0.3–10 mg) and the 
benefit of PFS was maintained in patients whose dose 
intensity during the study was lower possibly due to 
adverse events (AEs) (,7.5 mg/day, HR = 0.40, 95% 
CI, 0.31–0.52; $7.5 mg/day, HR = 0.45, 95% CI, 
0.37–0.56).74 Even longer-term data, at 18 months’ 
follow-up,  everolimus  plus  exemestane  improved 
PFS  versus  exemestane  alone.  There  was  an  esti-
mated 55% risk reduction for PFS (HR = 0.45; 95% 
CI, 0.38–0.54; P , 0.001) corresponding to a clini-
cally meaningful 4.63-month prolongation in median 
PFS, from 3.19 to 7.82 months.75 The AEs observed 
in  the  BOLERO-2  trial  are  consistent  with  those 
reported with everolimus and other rapamycin ana-
logs  and  include  stomatitis,  fatigue  and  asthenia, 
diarrhea, cough, pyrexia, and hyperglycemia.56,76 The 
most common grade 3 or 4 AEs in the everolimus plus 
exemestane and exemestane-only groups were stoma-
titis (8% vs. 1%, respectively), anemia (6% vs. ,1%, 
respectively),  dyspnea  (4%  vs.  1%,    respectively), 
hyperglycemia (4% vs. ,1%, respectively), fatigue 
(4% vs. 1%, respectively), and pneumonitis (3% vs. 0, 
respectively).72
Positive  results  for  TAMRAD,  a  randomized 
phase 2 trial of 111 patients investigating the combi-
nation of tamoxifen and everolimus in patients with 
hormone receptor-positive or progesterone receptor-
positive and HER2-negative mBC previously treated 
with an aromatase inhibitor and any numbers of pre-
vious chemotherapies, were recently reported.77 In the 
intent-to-treat analysis, the clinical benefit rate in the 
tamoxifen and everolimus group was 61.1% (95% CI, Yardley
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46.9–74.1) versus 42.1% (95% CI, 29.1–55.9) in the 
tamoxifen-only group, yielding a clinically significant 
difference (P = 0.045). With a 2-year median fol-
low-up, the time to progression was increased from 
4.5 months in the tamoxifen-only group to 8.6 months 
in the tamoxifen and everolimus group. The HR of 
progression was 0.54 (95% CI, 0.36–0.81, P = 0.002 
[exploratory]). Furthermore, the probability of sur-
vival was 54% in the tamoxifen and everolimus group 
and 30% in the tamoxifen-only group (HR = 0.45, 
95% CI, 0.24–0.81, P = 0.007).77 The safety profile of 
tamoxifen and everolimus was similar to that seen in 
other studies examining everolimus. Stomatitis, rash, 
diarrhea, anorexia, and infection were more common 
in the tamoxifen and everolimus group than in the 
tamoxifen-only group. Most AEs were graded 1 or 
2 in severity and could be managed without stopping 
everolimus. Grade 3 or 4 AEs were not more common 
in  tamoxifen-everolimus  recipients  than  in  tamox-
ifen-only recipients, further supporting the acceptable 
safety profile of tamoxifen-everolimus therapy.77 In 
addition to pain, the most common nonhematologic 
AEs  in  the  tamoxifen-everolimus  group  compared 
with the tamoxifen-alone group were fatigue (72% vs. 
53%, respectively), stomatitis (56% vs. 7%, respec-
tively),  rash  (44%  vs.  7%,  respectively),  anorexia 
(43% vs. 18%, respectively), and diarrhea (39% vs. 
11%,  respectively).77  The  most  common  hemato-
logic AEs in the tamoxifen-everolimus group com-
pared with the tamoxifen-alone group were decreased 
hemoglobin levels (69% vs. 35%, respectively) and 
decreased lymphocyte (48% vs. 21%, respectively) 
and leukocyte (54% vs. 18%, respectively) counts.77
mTOR inhibition, in combination with the selective 
ER downregulator fulvestrant, has also demonstrated 
promising  activity  in  patients  with  metastatic  ER-
positive breast cancer in which aromatase inhibitors 
were not effective. Interim results from this ongoing, 
single-arm, phase 2 study demonstrated a median time 
to progression of 8.6 months (of 11 evaluable patients, 
7  had  stable  disease  and  1  had  partial  response).78
In earlier-stage disease, letrozole plus everolimus 
or  letrozole  plus  placebo  was  recently  tested  in  a 
randomized, phase 2, neoadjuvant trial in 270 post-
menopausal women with ER-positive breast cancer. 
The  everolimus  combination  resulted  in  improved 
tumor response rate compared with letrozole/  placebo 
(68% vs. 59%, respectively, P = 0.06), as well as 
in a greater antiproliferative response (assessed by 
Ki67  expression)  than  placebo  (NCT00107016).79 
  Preclinical  data  together  with  these  positive  study 
results support future and ongoing clinical trials with 
mTOR inhibitors in mBC.
mTOR Inhibition in combination with 
Other signal Transduction Inhibitors
Another  potential  strategy  is  to  combine  mTOR 
inhibitors with other inhibitors of signal transduction 
pathways. The IGF-1 pathway is a major contributor 
to breast cancer pathogenesis. IGF-1R and the insu-
lin receptor substrate 1 frequently are expressed at 
increased levels in breast cancers and are associated 
with  chemoresistance  in  breast  cancer.21,80  mTOR 
integrates incoming signals from insulin or IGF via 
receptor-mediated activation of the PI3K/mTOR/Akt 
signaling pathway.16 An explanation for the limited 
activity of mTOR inhibitor monotherapy in breast can-
cer is that mTOR inhibition blocks negative feedback 
on IGF-1R signaling, impinging on PI3K and result-
ing in an increase in PI3K and Akt activation, which 
counteracts the inhibition of mTOR.81 Under normal 
conditions, IGF-1R–induced activation of the mTOR 
pathway  elicits  a  negative  feedback  loop  whereby 
mTOR/S6 kinase reduces insulin receptor substrate I 
levels, the main ligand for the IGF-1R.82 mTOR inhi-
bition interferes with feedback regulation of upstream 
signaling elements, thereby paradoxically activating 
IGF-I signaling and lessening the antitumor effective-
ness of mTOR inhibition. Treatment with the mTOR 
inhibitor rapamycin results in increased Akt activity 
and Akt phosphorylation at S473, which is dependent 
on IGF-1R and is associated with increased levels of 
insulin  receptor  substrate-1  (IRS-1).82  Along  these 
lines,  blockade  of  IGF-1  and  its  receptor,  IGF-1R, 
enhanced the antiproliferative effect of rapamycin, and, 
therefore, blocking IGF-1R appears to prevent mTOR 
inhibitor–induced feedback activation of PI3K/Akt and 
sensitizes tumor cell lines (including breast cancer) to 
the antiproliferative effects of mTOR inhibitors.82 As 
such, this preclinical evidence suggests that IGF-1R 
inhibitors  restore  sensitivity  in  breast  cancer  cells 
that are resistant to mTOR inhibition. Currently, the 
combination of mTOR inhibitors and IGF-1R inhibi-
tors is under study in several clinical trials, such as in 
the phase 1 trial evaluating temsirolimus in combina-
tion with cixutumumab (IMC-A12) against IGF-1R Combining mTOR inhibitor with chemotherapy or targeted therapy
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mentioned  previously  (Table  7)  (NCT00699491).29 
Similarly, treatment with weekly doses (50 to 70 mg) 
of RAD001 (everolimus) resulted in activation of the 
ERK/MAPK pathway in tumor biopsies from patients 
with  metastatic  cancer.83  Inhibition  of  MAPK  (via 
upstream inhibition of ERK with a MEK1/2 inhibi-
tor)  enhanced  the  antitumor  action  of  rapamycin.83 
In both instances, sensitivity to mTOR inhibitors was 
enhanced by a combination of agents that target mul-
tiple  aspects  of  the  PI3K/Akt/mTOR  pathway. The 
clinical utility of mTOR inhibitors may be limited by 
complex signaling feedback loops. Therefore, more 
clinical studies are needed with combined therapeutic 
approaches aimed at the mTOR pathway.
Other Investigational mTOR Inhibitors 
in Breast cancer
Additional novel inhibitors of the PI3K/Akt/mTOR 
pathway are being assessed in early-phase clinical 
trials. BEZ235, an investigational dual PI3K/mTOR 
inhibitor, has shown additive effects with trastuzumab 
and lapatinib in a PTEN knockdown breast cancer 
cell line.84 Additionally, BEZ235 has demonstrated 
antitumor  activity  in    trastuzumab-resistant  breast 
cancer cells with activating mutations in p110α, in 
trastuzumab-resistant breast cancer xenografts,85 and 
in  lapatinib-resistant  breast  cancer  cells  in  vitro.86 
This drug currently is being tested in phase 1 clinical 
trials of patients with mBC and other solid tumors 
alone  (NCT00620594)29  and  in  combination  with 
other agents (NCT01285466, NCT01248494).29
Ridaforolimus,  an  investigational  oral  mTOR 
inhibitor, improved PFS compared with placebo in 
patients with metastatic soft tissue or bone sarcomas 
who previously had a favorable response to chemo-
therapy in the SUCCEED trial (NCT00538239).29,87 
In October 2011, the FDA accepted the new drug 
application filing for ridaforolimus in the treatment 
of metastatic soft tissue or bone sarcoma in patients 
who had a favorable response to chemotherapy. The 
use  of  ridaforolimus  in  mBC  in  combination  with 
the IGF-1R inhibitor is currently being explored in a 
phase 2 study in HER2-negative, ER-positive, high-
proliferation breast cancer.29
conclusions
The PI3K/Akt/mTOR pathway contributes to estrogen 
independence, growth factor independence, and the 
development of resistance not only to chemotherapy 
but  also  to  endocrine  and  biologic  targeted  HER2 
agents in advanced breast cancer.   Inhibitors to mTOR 
have demonstrated antitumor activity in a variety of 
cancer  types,  including  hormone    receptor–positive, 
HER2-negative advanced breast cancer, RCC, PNET, 
renal  angiomyolipoma  associated  with  TSC  and   
SEGA  associated  with  TSC,  for  which  they  have 
gained  FDA  approval.  BOLERO-2  has  demon-
strated that the combination of mTOR inhibitors with 
endocrine therapies is a promising strategy, with the 
mTOR  inhibitor  everolimus,  in  combination  with 
exemestane, improving PFS in patients with hormone 
  receptor–positive advanced breast cancer refractory to 
nonsteroidal  aromatase  inhibitors.  Furthermore,  the  strat-
egy of combining mTOR inhibitors with other targeted 
agents or with cytotoxic chemotherapy has   produced 
signals of antitumor activity or has delayed the devel-
opment of resistance to these agents.   Selective patient 
criteria and rational selection of combination therapies 
may enhance the success of mTOR therapies based on 
information emerging from the many ongoing clini-
cal trials of mTOR combinations in mBC.   Designing 
effective combination therapies using mTOR   inhibitors 
together with different agents that target key molecu-
lar elements involved in breast cancer relies heavily 
on the identification of predictive markers that may 
provide a basis for individualized patient therapy. Bio-
marker-based evaluations in ongoing and future trials 
may identify the most beneficial therapeutic strategies 
for different patient   subgroups. Future clinical studies 
may stratify patients based on previous responsive-
ness or resistance to endocrine or trastuzumab therapy. 
Although mTOR inhibitors already play a critically 
important role in delivering more effective cancer ther-
apy, their role as partners to current treatment strategies 
for advanced breast cancer continues to be defined.
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